Advertisement


Georgina V. Long, MD, PhD, on Melanoma: Findings on Circulating Tumor DNA, Disease Recurrence, and Immunotherapy

ESMO Congress 2022

Advertisement

Georgina V. Long, MD, PhD, of the Melanoma Institute Australia, discusses results from the CheckMate 915 trial, an analysis of the pretreatment circulating tumor DNA, along with other clinical and translational baseline factors, and their association with disease recurrence in patients with stage IIIB–D/IV melanoma treated with adjuvant immunotherapy (Abstract 788O).



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
Checkmate 915 was a trial that included patients with resected stage three B to stage four melanoma. In this trial 1,844 patients were randomized to either receive nivolumab, a standard adjuvant therapy or nivolumab combined with a low dose of ipilimumab every six weeks. The primary endpoint for this trial was the relapse free survival in the intent to treat population and a co-primary endpoint was the relapse free survival in patients with PDL one expression in their tumor, less than 1%. This trial was negative and has been previously presented and published. Despite being negative though, patients had plasma and tumor collected at baseline and furthermore plasma collected at week 13 and week 29. At ESMO 2022 I presented the results of the analysis of the circulating tumor DNA using these baseline bio specimens in all 1,127 patients were included, which represented 61% of the intent to treat population. These patients all had treatment and also had baseline tissue and plasma for analysis. Using a patient specific, so using the patient's own tumor to identify what mutations were in their tumor and in their blood, we were able to create a patient specific panel to then detect circulating tumor DNA. We found that in the patient population where we looked at the circulating tumor DNA, the 1,127 patients, their baseline characteristics were exactly the same as that of the intent to treat population. The prevalence of circulating tumor DNA positivity in this population was 16%. We also saw that the prevalence of circulating tumor DNA was slightly higher in the higher sub stage of stage three, as well as those with a higher ECOG performance status. We did not see a higher prevalence of circulating tumor DNA in any other subgroup, including tumor mutation burden, positive or negative, patients with PDL one expression greater than or less than 1%, or BRAF mutation status although there was a slight trend to a higher circulating tumor DNA in that population. We then analyzed the circulating tumor DNA and looked at the relapse free survival and distant metastasis free survival by the CT DNA positivity and found a very clear result with the Kaplan-Meier analysis that those with baseline positive circulating tumor DNA had a much poorer relapse free survival and a much poorer distant metastasis free survival. Importantly, the circulating tumor DNA positivity predicted early recurrence best with higher sensitivity and specificity at the early time points rather than at the later time points three months versus 24 months. Because this trial was negative, we did not see a difference in the treatment arms nivolumab versus nivolumab plus ipilimumab in terms of the circulating tumor DNA positivity and its prediction of relapse. Lastly, we then combined the circulating tumor DNA with other tissue biomarkers, including the interferon gamma expression tumor mutation burden in the baseline tissue and found that by combining all three circulating tumor DNA and the interferon gamma and tumor mutation burden, we were much better able to predict recurrence. And had eight subgroups of patients with more accurate prediction of recurrence, the best performing group being the circulating tumor DNA negative interferon gamma baseline tissue expression high and high tumor mutation burden at baseline. Ongoing steps will be to come up with a composite biomarker analysis or predictive nomogram. And also we were looking at the circulating tumor DNA in longitudinal analysis from this trial to predict recurrence. I'd like to thank the patients and their families for their contribution to this trial.

Related Videos

Gynecologic Cancers

Ana Oaknin, MD, PhD, on Cervical Cancer: New Findings on Cemiplimab in Recurrent or Metastatic Disease

Ana Oaknin, MD, PhD, of Barcelona’s Vall d’Hebron University Hospital, discusses an analysis of long-term survival from the EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9 trial. Cemiplimab-rwlc is the first immunotherapy to demonstrate an overall survival benefit as a second-line monotherapy for patients with recurrent or metastatic cervical cancer previously treated with platinum-based chemotherapy but not immunotherapy. The benefit was sustained in this population (Abstract 519MO).

Breast Cancer
Genomics/Genetics

Antonio Marra, MD, on Metastatic Breast Cancer: Patterns of Genomic Instability and Their Effect on Treatment

Antonio Marra, MD, of Memorial Sloan Kettering Cancer Center, discusses a mutational signature analysis that reveals patterns of genomic instability linked to resistance to endocrine therapy with or without CDK4/6 inhibition in patients with estrogen receptor–positive/HER2-negative metastatic breast cancer (Abstract 210O).

Pancreatic Cancer

Christelle de la Fouchardiere, MD, on Pancreatic Ductal Adenocarcinoma: Phase III Trial Results With Gemcitabine Plus Paclitaxel

Christelle de la Fouchardiere, MD, of France’s Centre Léon Bérard, discusses phase III findings from the PRODIGE 65–UCGI 36–GEMPAX UNICANCER study, which evaluated whether the combination of gemcitabine and paclitaxel improves overall survival compared with gemcitabine alone in patients with metastatic pancreatic ductal adenocarcinoma after FOLFIRINOX failure or intolerance (Abstract LBA60).

Bladder Cancer
Immunotherapy

Jonathan E. Rosenberg, MD, on Urothelial Cancer: Results From EV-103, Cohort K on Enfortumab Vedotin and Pembrolizumab

Jonathan E. Rosenberg, MD, of Memorial Sloan Kettering Cancer Center, discusses recent findings on the safety and antitumor activity of enfortumab vedotin-ejfv given intravenously as monotherapy or in combination with pembrolizumab to previously untreated cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer (Abstract LBA73).

Skin Cancer

John B.A.G. Haanen, MD, PhD, on Melanoma: Phase III Data on Treatment With Tumor-Infiltrating Lymphocytes vs Ipilimumab

John B.A.G. Haanen, MD, PhD, of The Netherlands Cancer Institute, discusses recent phase III findings, which show that tumor-infiltrating lymphocytes (TILs) improve progression-free survival compared with ipilimumab by 50% in patients with advanced melanoma after not responding to anti–PD-1 treatment. Around 50% of TIL-treated patients had a response, and 20% had a complete response (Abstract LBA3).

Advertisement

Advertisement



Advertisement